Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

HIV/HBV/HCV Test Kits Market Outlook

The HIV/HBV/HCV test kits market size is projected to be valued at US$ 6,568.3 million in 2023 and is expected to rise to US$ 11,573.9 million by 2033. The sales of HIV/HBV/HCV test kits are expected to grow at a significant CAGR of 5.8% during the forecast period. Various trend positively influencing the HIV/HBV/HCV test kits market are:

A wide range of micro and macroeconomic factors are influencing the growth of the HIV/HBV/HCV test kits market. The most influential factor is the extensive awareness campaigns carried out by various non-governmental organizations around the world.

These non-governmental organizations are attempting to reach out to people in remote areas and educate them about immunodeficiency diseases and the methods for detecting and preventing them. This has resulted in a significant increase in global demand for HIV/HBV/HCV test kits.

One of the key development factors for the global HIV/HBV/HCV test kits market is rising demand for point-of-care testing for HIV, HBV, and HCV.

POC testing technologies are now more efficient, widely available, and reasonably priced. Early HIV detection can be extremely beneficial to the patient because it facilitates the doctor to design a more effective treatment plan.

Governments and regulating authorities all over the world have launched initiatives and campaigns to educate and treat people. They are supplying these kits for free in order to raise awareness.

Increasing investments by leading players to make these HIV/HBV/HCV test kits more efficient, reliable, and affordable has contributed to the global market's overall growth. The ease of use of these test kits has increased their popularity in medical centers and hospitals.

Regardless of the various factors influencing the growth of this market, there are several key issues that must be addressed in order to facilitate future growth. The relatively high total costs of developing and using HIV/HBV/HCV test kits, as well as reimbursement policies, are limiting the market's growth.

However, the market is expanding as a result of rising product approvals, alliances, and acquisitions by major companies.

Attributes Details
HIV/HBV/HCV Test Kits Market CAGR 5.8 %
HIV/HBV/HCV Test Kits Market Valuation (2023) US$ 6,568.3 million
HIV/HBV/HCV Test Kits Market Valuation (2033) US$ 11,573.9 million 2033

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed till June 2022?

Market Statistics Details
H1,2021 (A) 6.54%
H1,2022 Projected (P) 6.44%
H1,2022 Outlook (O) 6.24%
BPS Change: H1,2022 (O) - H1,2022 (P) (-) 20 ↓
BPS Change: H1,2022 (O) - H1,2021 (A) (-) 30 ↓

The comparative analysis and market growth rate of global HIV/HBV/HCV test kits market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 20 BPS. Furthermore, a negative BPS growth is expected in H1-2022 over H1- 2021 duration with 30 Basis Point Share (BPS).

The decline in the BPs values observed can be attributed to the disruptions in supply chain and distribution networks globally due to the global pandemic. Moreover, the availability of self-test kits is limited to the developed nations, and thus poses a dip in demand, owed to the high disease epidemiology in the developing nations and the high demand generated through the same.

The key developments in the market include the launch of a real-time fluorescence PCR technology used for nucleic acid qualitative detection of HBV, and chip-based assays for HCV, such as the Truenat HCV.

Growing disease epidemiology of viral and infectious diseases, and the increasing efforts by regional governments to extend outreach for detection is anticipated to provide a positive growth outlook for the market during the projected period.

2018 to 2022 HIV/HBV/HCV Test Kits Market Outlook in Comparison to 2023 to 2033 Growth Forecast

The world has seen significant increase in incidence of HIV and hepatitis, and this is expected to majorly drive HIV/HBV/HCV test kit consumption. With HIV and hepatitis infections being a major public health issue across the world, demand for efficient diagnostic services for these diseases is prominent.

Sales of HIV/HBV/HCV test kits rose at a CAGR of 6.8% from 2018 to 2022. Governments and NGOs across the world are taking initiatives to raise awareness about STD testing and its importance in the fight against HIV and hepatitis. This has led to substantial increase in awareness on a global level, with initiatives such as 'Start Talking. Stop HIV'.

Rising research & developments in the medical diagnostics industry, increasing incidence of HIV and hepatitis, increasing awareness among the general population, rising healthcare expenditure, technological advancements in diagnostics, etc., are some major factors that are expected to drive consumption of HIV/HBV/HCV test kits.

Demand for HIV/HBV/HCV test kits is expected to be majorly influenced by developing and emerging markets, with low- and middle-income countries such as Brazil, India, and China leading the way.

Lack of awareness and inadequate availability of test kits in less-developed economies is expected to restrain demand for HIV/HBV/HCV test kits to a certain extent. Market witnessed a significant downfall during the pandemic period as supply lines were cut short. Nevertheless, the market is anticipated to recover swiftly and contribute a US$ 11,573.9 million revenue share by 2033.

Overall, the HIV/HBV/HCV test kits market is predicted to expand at a CAGR of 5.8% from 2023 to 2033.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Key Trends are Expected to Majorly Influence Demand for HIV/HBV/HCV Test Kits?

Innovations and Product developments

The burden of HIV, HBV, and HCV infections is still disproportionately high in developing economies (India, sub-Saharan Africa, Brazil) where co-infection rates are high. For HIV, HBV, and HCV serological testing, high analytical performance multiplex rapid diagnostic techniques may improve the cascade of screening and lead to more cost-effective linkage to care. Such a testing strategy may be especially beneficial for hard-to-reach high-risk populations and may also increase the impact of self-testing on public health. For instance, the prototype Triplex HIV/HCV/HBsAg finger-stick whole-blood self-test may provide a simple, quick, and inexpensive way to detect HIV, HBV, and HCV infections. It might be particularly useful for enhancing the detection of three closely related endemic viral diseases. These choices might boost screening programs, reducing the price of diseases brought on by untreated HIV, HBV, or HCV infections in the future. They might also help with efforts to treat these infections and perhaps even eradicate HCV infection.

Which Restraining Factors Could Impede Market Growth?

Lack of Awareness to Hinder Sales of HIV Test Kits

Awareness about the treatment of HIV in less developed economies such as Brazil, India, and African nations is very limited due to lack of developed healthcare infrastructure. This has adversely affected HIV/HBV/HCV test kit sales in these economies and restrained overall market potential on a global level.

The asymptomatic nature of infections has also hampered the HIV/HBV/HCV test kits market. Poor healthcare facilities, high costs of treatments and medicines, and low STD testing are some other factors that may restrain HIV test kit sales over the forecast period.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Comparative view of HIV/HBV/HCV Test Kits Market

HIV/HBV/HCV Test Kits Market:

Attributes HIV/HBV/HCV Test Kits Market
CAGR (2023 to 2033) 5.8%
Market Value (2033) US$ 11,573.9 million
Growth Factor The rising prevalence of chronic diseases, as well as technological innovations and advancements in screening procedures, are driving market growth.
Opportunity Increased public awareness, increased government cancer-fighting initiatives, and rising healthcare costs are expected to drive the market forward.

Low dosage Hydrate Inhibitors Market:

Attributes Low dosage Hydrate Inhibitors Market
CAGR (2023 to 2033) 8.1%
Market Value (2033) US$ 127.45 million.
Growth Factor Low dosage hydrate inhibitors' ability to reduce transportation and handling costs through decreased delivery frequency and chemical consumption is expected to drive market sales.
Opportunity Increased crude oil exploration and production are expected to drive market growth, as low dosage hydrate inhibitors are widely used in extraction processes to reduce hydrate formation in the systems.

Kinase Inhibitors for Cancer Treatment Market:

Attributes Kinase Inhibitors for Cancer Treatment Market
CAGR (2023 to 2033) 10.5%
Market Value (2033) US$ 122,133.64 million
Growth Factor Pharmaceutical companies are currently investing heavily in R&D to develop improved kinase inhibitors. This is currently propelling market growth.
Opportunity Massive technological advancements are taking place in the healthcare sector, particularly in the field of cancer treatment.

Country-wise Analysis

Growing preference for rapid screening is anticipated to stimulate sales of rapid HIV test kits in the country.

HIV has been a public health issue in the United States for quite some time, and while the number of new cases has decreased over the past decades, the rate of new infection detections remains a source of concern. Advanced healthcare infrastructure, increased patient awareness, and rising adoption of effective rapid testing kits are some of the major factors driving the HIV/HBV/HCV testing systems market in the United States.

United States Market Size (US$million/billion) by End of Forecast Period (2033) US$ 3,455 million
United States Market Absolute Dollar Growth (US$ million/billion) US$ 135.1 million
CAGR % 2017 to 2022 7.7%
CAGR % 2023 to End of Forecast (2033) 5.9%

Canada is expected to account for US$ 479.0 million of the North American HIV/HBV/HCV Test Kits market.

Canada is expected to have a significant share due to advanced diagnostic tools, high awareness of disease and diagnostic devices, a strong presence of industry players in the region, improved healthcare infrastructure, and increased awareness among healthcare industry stakeholders about available technologies in the region. For example, the Public Health Agency of Canada investigated 28 cases of severe acute hepatitis in children in Canada that met the national case definition between April and September 2022. As a result, an increase in hepatitis cases is expected to lead to an increase in diagnostic testing, ultimately driving market growth in the region.

Canada Market Size (US$ million/billion) by End of Forecast Period (2033) US$ 479.0 million
Canada Market Absolute Dollar Growth (US$ million/billion) 21.70 million
CAGR % 2017 to 2022 9.1%
CAGR % 2023 to End of Forecast (2033) 6.4%

Over the next few years, the Asia Pacific market for HIV/HBV/HCV test kits is expected to grow rapidly.

The region's ever-increasing population is the primary driving factor for the market. China and India are two of the world's most densely populated countries in Asia Pacific. A dense population is more likely to be infected with an immunodeficiency virus. Naturally, awareness and availability of HIV/HBV/HCV test kits are expected to grow in the Asia Pacific market.

China Market Size (US$ million/billion) by End of Forecast Period (2033) US$ 1032.4 million
China Market Absolute Dollar Growth (US$ million/billion) US$ 28.4 million
CAGR % 2017 to 2022 3.8%
CAGR % 2023 to End of Forecast (2033) 5.5%

India is the world's second-most populous country and ranks third in terms of HIV infections, with over 2 million people infected. Instances of new HIV infections have decreased in recent decades, but they remain a source of concern given the country's large population.

Increasing STD testing awareness and developing healthcare infrastructure are expected to have a significant impact on HIV/HBV/HCV test equipment demand in India. Over the next few years, the market in India is likely to remain extremely profitable for HIV/HBV/HCV test kit providers.

HIV/HBV/HCV Test Kits Market - Category-wise Insights

Relative to conventional testing, assays have been proved to deliver reliable results, even with microscopic samples.

Segment to witness a growth of 6.4% during 2023 to 2033

In 2022, the assay-based test kits segment held the major share of the market. Assay kits are the first line of patients testing which is naturally stimulating its growth. Furthermore, in most developing countries, healthcare professionals and patients rely on assay-based testing results. Besides, there have been advancements in assay-based test kits. The Xpert HCV Viral Load Fingerstick Test from Cepheid, for example, is a point-of-care test that employs the GeneXpert System. This point-of-care test looks for HCV RNA in finger-stick whole blood capillaries (or assay). This type of HCV testing involves drawing capillary blood from the patient via finger prick into a Minivette collection device, which is then processed in a GeneXpert device at or near the point-of-care testing location.
Blood sample tops the sample segment and is expanding at a rapid rate of 6.1% CAGR during the forecast period.

Blood samples are highly prevalent in testing or diagnosis procedures due to ease in storing and their high reliability on patients sample profile. Most AIDS and AIDS-related complex (ARC) patients, as well as many asymptomatic individuals belonging to high-risk groups, have been found to have antibodies to the human immunodeficiency virus (HIV). The presence of these HIV antibodies in human blood and plasma samples is frequently tested using enzyme-linked immunosorbent assays (ELISA). INNO-LIA HIV I/II Score, for example, is a Line Immuno Assay (LIA) that detects the presence of antibodies against HIV-1, including group O and HIV-2, in human blood or plasma. INNO-HIV LIA's I/II Score distinguishes between HIV-1 and HIV-2 infections. It is intended to be used in conjunction with an anti-HIV screening process on reactive specimens. As a result, demand for assay-based test kits has increased.

Competitive Landscape

Given the presence of a few companies operating globally and regionally, the HIV/HBV/HCV test market is slightly fragmented. The competitive landscape includes an examination of a few well-known international and local companies that hold market share. Abbott Laboratories, Danaher Corporation, BioMerieux SA, Bio-Rad Laboratories Inc, Diasorin S.p.A, F. Hoffmann-La Roche AG, Hologic Inc, MedMira Inc, Qaigen Inc, Grifols SA, Sysmex Corporation, and Siemens Healthineers are key market players.

  • Gilead Sciences, Inc. joined a public-private partnership with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration of Brigham and Women's Hospital, Harvard Medical School, and Beth Israel Deaconess Medical Center, in September 2022. The multi-year initiative to take a phased approach to addressing barriers to viral hepatitis diagnosis and care in primary healthcare institutions in Vietnam and the Philippines, both of which have high hepatitis B and C burdens.
  • Roche introduced the Elecsys HCV Duo immunoassay in July 2022. Elecsys HCV Duo is one of the first commercially available immunoassays that can determine hepatitis C virus (HCV) antigen and antibody status simultaneously and independently.

Scope of Report

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2018 to 2022
Market Analysis US$ million for Value
Key Countries Covered USA, Canada, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa
Key Segments Covered
  • Test Kit Type
  • Sample
  • End User
  • Region
Key Companies Profiled BioMerieux SA, Bio-Rad Laboratories Inc, Diasorin S.p.A, F. Hoffmann-La Roche AG, Hologic Inc, MedMira Inc, Qaigen Inc, Grifols SA, Sysmex Corporation, and Siemens Healthineers
Report Coverage Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing Available upon Request

HIV/HBV/HCV Test Kits Market by Solution

HIV/HBV/HCV Test Kits Market by Test Kit Type:

  • Assay-based Test Kits
  • Rapid Test Kits

HIV/HBV/HCV Test Kits Market by Sample:

  • Blood
  • Urine
  • Saliva

HIV/HBV/HCV Test Kits Market by End User:

  • HIV/HBV/HCV Test Kits for Hospitals
  • HIV/HBV/HCV Test Kits for Clinics
  • HIV/HBV/HCV Test Kits for Diagnostic Laboratories
  • HIV/HBV/HCV Test Kits for Government Organizations and NGOs
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the Estimated Size of the HIV/HBV/HCV Test Kits Market?

The projected HIV/HBV/HCV test kits market size is expected to reach US$ 6,568.3 million in 2023, with a forecasted surge to surpass US$ 11,573.9 million by 2033.

How has the HIV/HBV/HCV Test Kits Market Evolved over the Past Five Years?

The HIV/HBV/HCV test kits market recorded a 6.8% CAGR from 2018 to 2022.

What Factors are Driving the Growth of the HIV/HBV/HCV Test Kits Market?

The HIV/HBV/HCV test kits market expansion is propelled by heightened awareness, improved diagnostics accessibility, and global health initiatives.

What are the Key Challenges faced by HIV/HBV/HCV Test Kits Market Players?

Prominent challenges for HIV/HBV/HCV test kits market players include affordability barriers, limited healthcare infrastructure, and regulatory complexities.

Which Regions are Witnessing the Maximum Adoption of HIV/HBV/HCV Test Kits?

HIV/HBV/HCV test kits are predominantly adopted in high-burden regions, including Southeast Asia and parts of Eastern Europe.

Table of Content

1. Executive Summary | HIV/HBV/HCV Test Kits Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Kit Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Test Kit Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Kit Type, 2023 to 2033

        5.3.1. Assay-based Test Kits

        5.3.2. Rapid Test Kits

    5.4. Y-o-Y Growth Trend Analysis By Test Kit Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Test Kit Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sample

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Sample, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sample, 2023 to 2033

        6.3.1. Blood

        6.3.2. Urine

        6.3.3. Saliva

    6.4. Y-o-Y Growth Trend Analysis By Sample, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Sample, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Clinics

        7.3.3. Diagnostic Laboratories

        7.3.4. Government Organizations and NGOs

        7.3.5. Others

    7.4. Y-o-Y Growth Trend Analysis By End User , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Test Kit Type

        9.2.3. By Sample

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Test Kit Type

        9.3.3. By Sample

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Test Kit Type

        10.2.3. By Sample

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Test Kit Type

        10.3.3. By Sample

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. United Kingdom

            11.2.1.2. Spain

            11.2.1.3. Germany

            11.2.1.4. Italy

            11.2.1.5. France

            11.2.1.6. Rest of Europe

        11.2.2. By Test Kit Type

        11.2.3. By Sample

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Test Kit Type

        11.3.3. By Sample

        11.3.4. By End User

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. India

            12.2.1.4. South Korea

            12.2.1.5. Rest of Asia Pacific

        12.2.2. By Test Kit Type

        12.2.3. By Sample

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Test Kit Type

        12.3.3. By Sample

        12.3.4. By End User

    12.4. Key Takeaways

13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. South Africa

            13.2.1.2. GCC Countries

            13.2.1.3. Rest of Middle East and Africa

        13.2.2. By Test Kit Type

        13.2.3. By Sample

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Test Kit Type

        13.3.3. By Sample

        13.3.4. By End User

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Test Kit Type

            14.1.2.2. By Sample

            14.1.2.3. By End User

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Test Kit Type

            14.2.2.2. By Sample

            14.2.2.3. By End User

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Test Kit Type

            14.3.2.2. By Sample

            14.3.2.3. By End User

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Test Kit Type

            14.4.2.2. By Sample

            14.4.2.3. By End User

    14.5. United Kingdom

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Test Kit Type

            14.5.2.2. By Sample

            14.5.2.3. By End User

    14.6. Spain

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Test Kit Type

            14.6.2.2. By Sample

            14.6.2.3. By End User

    14.7. Germany

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Test Kit Type

            14.7.2.2. By Sample

            14.7.2.3. By End User

    14.8. Italy

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Test Kit Type

            14.8.2.2. By Sample

            14.8.2.3. By End User

    14.9. France

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Test Kit Type

            14.9.2.2. By Sample

            14.9.2.3. By End User

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Test Kit Type

            14.10.2.2. By Sample

            14.10.2.3. By End User

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Test Kit Type

            14.11.2.2. By Sample

            14.11.2.3. By End User

    14.12. India

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Test Kit Type

            14.12.2.2. By Sample

            14.12.2.3. By End User

    14.13. South Korea

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Test Kit Type

            14.13.2.2. By Sample

            14.13.2.3. By End User

    14.14. South Africa

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Test Kit Type

            14.14.2.2. By Sample

            14.14.2.3. By End User

    14.15. GCC Countries

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Test Kit Type

            14.15.2.2. By Sample

            14.15.2.3. By End User

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Test Kit Type

        15.3.3. By Sample

        15.3.4. By End User

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Hoffmann-La Roche Ltd.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Abbott Laboratories

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. bioMérieux SA

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Bio-Rad Laboratories Inc.

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. QIAGEN

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Hologic Inc.

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Meridian Bioscience, Inc.

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Siemens AG

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Creative Diagnostics

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

HIV Antivirals Market

Published : June 2022

Healthcare

HIV Diagnostics Market

Published : May 2022

Explore Healthcare Insights

View Reports

HIV/HBV/HCV Test Kits Market